Enhanced Apoptosis of Ovarian Cancer Cells Via Nanocarrier-mediated Codelivery of SiRNA and Doxorubicin

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2012 Aug 14

PMID 22888237

Citations 29

Authors

Seyin Zou

Nuo Cao

Du Cheng

Rongqin Zheng

Jin Wang

Kangshun Zhu

Xintao Shuai

Affiliations

Soon will be listed here.

Abstract

A folate conjugated ternary copolymer, FA-PEG-PEI-PCL, of poly(ethylene glycol) (PEG), poly(ethylene imine) (PEI), and poly(ɛ-caprolactone) (PCL) was synthesized. The copolymer self-assembled into cationic micelles capable of co-delivering siRNA and the anticancer drug doxorubicin (DOX). This dual functional nanocarrier demonstrated low cytotoxicity and high performance in drug/siRNA delivery. Upon the codelivery of siRNA, targeting the Bcl-2 gene, and DOX, using the folate-targeted nanocarrier, DOX-induced apoptosis in the skov-3 cells overexpressing folate receptor was significantly enhanced through a mechanism of downregulating the antiapoptotic protein Bcl-2, while simultaneously upregulating the proapoptotic protein Bax. This work suggested that the combination of Bcl-2 siRNA and DOX therapies is feasible, based on our dual functional nanocarrier, which set up a good basis for a future in vivo test.

Citing Articles

Artificial Intelligence Application for Anti-tumor Drug Synergy Prediction.

Peng Z, Ding Y, Zhang P, Lv X, Li Z, Zhou X Curr Med Chem. 2024; 31(40):6572-6585.

PMID: 39420717 DOI: 10.2174/0109298673290777240301071513.

Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.

Korzun T, Moses A, Diba P, Sattler A, Olson B, Taratula O Small. 2023; 20(41):e2301776.

PMID: 37518857 PMC: 10827528. DOI: 10.1002/smll.202301776.

Nanoparticle-Based Combination Therapy for Ovarian Cancer.

Wu Y, Yang Y, Lv X, Gao M, Gong X, Yao Q Int J Nanomedicine. 2023; 18:1965-1987.

PMID: 37077941 PMC: 10106804. DOI: 10.2147/IJN.S394383.

The Impact of Metal Nanoparticles on Female Reproductive System: Risks and Opportunities.

Aloisi M, Rossi G, Colafarina S, Guido M, Cecconi S, Poma A Int J Environ Res Public Health. 2022; 19(21).

PMID: 36360633 PMC: 9655349. DOI: 10.3390/ijerph192113748.

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy.

Al Bostami R, Abuwatfa W, Husseini G Nanomaterials (Basel). 2022; 12(15).

PMID: 35957103 PMC: 9370272. DOI: 10.3390/nano12152672.

References

Lima R, Martins L, Guimaraes J, Sambade C, Vasconcelos M . Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004; 11(5):309-16. DOI: 10.1038/sj.cgt.7700706. View

Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

Poulaki V, Mitsiades C, Joussen A, Lappas A, Kirchhof B, Mitsiades N . Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. Am J Pathol. 2002; 161(6):2229-40. PMC: 1850903. DOI: 10.1016/s0002-9440(10)64499-9. View

Scatena C, Stewart Z, Mays D, Tang L, Keefer C, Leach S . Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem. 1998; 273(46):30777-84. DOI: 10.1074/jbc.273.46.30777. View

Cammas S, Nagasaki Y, Kataoka K . Heterobifunctional poly(ethylene oxide): synthesis of alpha-methoxy-omega-amino and alpha-hydroxy-omega-amino PEOs with the same molecular weights. Bioconjug Chem. 1995; 6(2):226-30. DOI: 10.1021/bc00032a011. View

Haley B, Frenkel E . Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008; 26(1):57-64. DOI: 10.1016/j.urolonc.2007.03.015. View

Chauhan S, Kumar D, Jaggi M . Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res. 2009; 2:21. PMC: 2804676. DOI: 10.1186/1757-2215-2-21. View

Cheng D, Cao N, Chen J, Yu X, Shuai X . Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials. 2011; 33(4):1170-9. DOI: 10.1016/j.biomaterials.2011.10.057. View

Sudimack J, Lee R . Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000; 41(2):147-62. DOI: 10.1016/s0169-409x(99)00062-9. View

10.

Clementi M, Giardina B, Di Stasio E, Mordente A, Misiti F . Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 2003; 23(3B):2445-50. View

11.

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L . Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56(2):185-229. DOI: 10.1124/pr.56.2.6. View

12.

Singal P, Iliskovic N . Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339(13):900-5. DOI: 10.1056/NEJM199809243391307. View

13.

Wang Y, Gao S, Ye W, Yoon H, Yang Y . Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006; 5(10):791-6. DOI: 10.1038/nmat1737. View

14.

Wang S, Konorev E, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B . Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem. 2004; 279(24):25535-43. DOI: 10.1074/jbc.M400944200. View

15.

Dantzig A, Shepard R, Cao J, Law K, Ehlhardt W, Baughman T . Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996; 56(18):4171-9. View

16.

Giuliano M, Lauricella M, Vassallo E, Carabillo M, Vento R, Tesoriere G . Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci. 1998; 39(8):1300-11. View

17.

Zhu C, Jung S, Luo S, Meng F, Zhu X, Park T . Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials. 2009; 31(8):2408-16. DOI: 10.1016/j.biomaterials.2009.11.077. View

18.

Yallapu M, Jaggi M, Chauhan S . Scope of nanotechnology in ovarian cancer therapeutics. J Ovarian Res. 2010; 3:19. PMC: 2924337. DOI: 10.1186/1757-2215-3-19. View

19.

Chen G, Chen W, Wu Z, Yuan R, Li H, Gao J . MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials. 2009; 30(10):1962-70. DOI: 10.1016/j.biomaterials.2008.12.043. View

20.

Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A . Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 1997; 57(1):62-7. View